Abstract:

Background: In this study, we aimed to evaluate the effect of Adalimumab treatment on iron parameters and the course of anemia in inflammatory bowel disease (IBD). Materials and Methods: Thirty-three patients (19 Crohn's and 14 ulcerative colitis) who received Adalimumab treatment for IBD who were followed up in the Gastroenterology outpatient clinic of Sanko University Faculty of Medicine between 2016-2019 were included in the study. Age, gender, laboratory data (blood hemoglobin (Hb), hematocrit (Htc), leukocyte (WBC), platelet (Plt), iron (Fe), iron binding capacity (DBK), transferrin saturation, ferritin, C - reaktif protein ( CRP) and sedimentation levels) of the patients were recorded. Pre-treatment and 6th month values were compared. Clinical activity the efficacy of treatment was evaluated by comparing the mean partial Mayo score (pMayo) for ulcerative colitis and the mean Harvey-Bradshaw Index (HBI) scores in Crohn’s patients. SPSS 26.0 program was used in the analysis of variables. Variables were analyzed at a 95% confidence level and a p value of less than 0.05 was considered to be significant. Results: Decrease in sedimentation, CRP and Plt values after treatment and significant increase was found in Hb, Htc and iron values, respectively. An increase in transferrin saturation was observed. However, this did not create a statistically significant difference. It was determined that the increase in Hb and Htc values was more in the ulcerative colitis group. A significant decrease was found in clinical pMayo and HBI scores. Conclusions: Anemia improves in patients treated with Adalimumab for IBD, and this improvement is more pronounced in patients with ulcerative colitis.